98 related articles for article (PubMed ID: 7618188)
1. An improved method for the quantification and recovery of rat uterine nuclear type II [3H]estradiol binding sites immobilized on a glass fiber matrix.
Densmore CL; Tiller AA; Gregory RR; Schauweker TH; Webb B; Markaverich BM
Steroids; 1995 Feb; 60(2):214-9. PubMed ID: 7618188
[TBL] [Abstract][Full Text] [Related]
2. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
Markaverich BM; Gregory RR
Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
[TBL] [Abstract][Full Text] [Related]
3. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: a simple method for the quantitation of type I and type II sites by [3H]estradiol exchange.
Markaverich BM; Williams M; Upchurch S; Clark JH
Endocrinology; 1981 Jul; 109(1):62-9. PubMed ID: 7238414
[TBL] [Abstract][Full Text] [Related]
5. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol.
Maybruck WM; Markaverich BM
Steroids; 1997 Mar; 62(3):321-30. PubMed ID: 9071742
[TBL] [Abstract][Full Text] [Related]
6. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth.
Markaverich BM; Gregory RR; Alejandro MA; Varma RS; Johnson GA; Middleditch BS
J Steroid Biochem; 1989 Nov; 33(5):867-76. PubMed ID: 2601331
[TBL] [Abstract][Full Text] [Related]
7. Chromatographic resolution of the type II estrogen binding site and a tyrosinase-like enzymatic activity from rat uterine nuclei.
Densmore CL; Schauweker TH; Gregory RR; Webb B; Garcia E; Markaverich BM
Steroids; 1994 Apr; 59(4):282-7. PubMed ID: 8079383
[TBL] [Abstract][Full Text] [Related]
8. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
9. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of [3H]estradiol binding sites in the rat prostate: properties and distribution of type I and type II sites.
Yu M; Cates J; Leav I; Ho SM
J Steroid Biochem; 1989 Sep; 33(3):449-57. PubMed ID: 2779236
[TBL] [Abstract][Full Text] [Related]
11. An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues.
Markaverich BM; Roberts RR; Alejandro MA; Clark JH
Cancer Res; 1984 Apr; 44(4):1515-9. PubMed ID: 6704964
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogenic effect of gestrinone as an inhibitor of [3H]-estradiol binding to nuclear type II sites.
Ohno Y; Kitagawa I; Tamura H; Hosoda S; Yamashita S; Honjo H; Okada H
Gynecol Obstet Invest; 1991; 31(2):97-101. PubMed ID: 2037266
[TBL] [Abstract][Full Text] [Related]
13. Cytosol type II sites in the rat uterus: interaction with an endogenous ligand.
Markaverich BM; Adams NR; Roberts RR; Alejandro M; Clark JH
J Steroid Biochem; 1987 Dec; 28(6):599-608. PubMed ID: 2826918
[TBL] [Abstract][Full Text] [Related]
14. [Type-I and -II estradiol binding sites in the endometrium during blastocyst implantation].
Bernal A; Calzada L; Hicks JJ; Velázquez A
Ginecol Obstet Mex; 1989 Apr; 57():103-8. PubMed ID: 2487303
[TBL] [Abstract][Full Text] [Related]
15. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
[TBL] [Abstract][Full Text] [Related]
16. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition.
Markaverich BM; Roberts RR; Alejandro MA; Johnson GA; Middleditch BS; Clark JH
J Steroid Biochem; 1988; 30(1-6):71-8. PubMed ID: 3386279
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4.
Shoulars K; Rodriguez MA; Crowley J; Turk J; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):1-8. PubMed ID: 16621524
[TBL] [Abstract][Full Text] [Related]
18. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
[TBL] [Abstract][Full Text] [Related]
19. Estrogen dependent induction of low affinity binding sites in the nuclear fraction of rat uterus.
De Hertogh R; Ekka E; Vanderheyden I
J Steroid Biochem; 1986 Jun; 24(6):1171-7. PubMed ID: 3736044
[TBL] [Abstract][Full Text] [Related]
20. Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of noble rats.
Ho SM; Yu M
Cancer Res; 1993 Feb; 53(3):528-32. PubMed ID: 7678774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
